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31 Abstract
Background: We aimed to describe patterns of use and characteristics of 10 commonly used 
antidepressants for the period 2009-2014 in Denmark, Germany, Spain, and Sweden. 
Methods: Adult initiators from 2009 to 2014 of each study antidepressant were identified in four 
countries using five data sources: the Danish National registers, GePaRD (Germany), EpiChron 
(Aragon, Spain), SIDIAP (Catalonia, Spain), and the Swedish National Registers. The study 
included 10 study antidepressants: citalopram, escitalopram, fluoxetine, paroxetine, sertraline, 
duloxetine, venlafaxine, amitriptyline, mirtazapine, and agomelatine. 
Results: Citalopram was the most prescribed study antidepressant, followed by mirtazapine. 
Paroxetine and agomelatine were the least prescribed antidepressants. Mirtazapine was widely 
used among older antidepressant initiators with higher percentages of comorbidities at baseline, 
and fluoxetine was used among young patients. Citalopram and amitriptyline had the lowest 
percentage of multiple antidepressant use in the 12 months prior to the current treatment episode, 
while agomelatine, duloxetine, and venlafaxine had the highest percentage of multiple 
antidepressant use in the year prior to the current treatment episode.    
Limitations: The most important limitations are exposure information based on filled 
prescriptions, focus on antidepressant initiators only, lack of information on the indication, and 
heterogeneity of the type of data across data sources.    
Conclusions: Results of this study including 4.8 million study antidepressant initiators of study 
antidepressants suggest that citalopram and mirtazapine are the most commonly prescribed 
antidepressants. Agomelatine and paroxetine were the least used antidepressants in the 
4participating populations. Mirtazapine was the antidepressant most commonly prescribed among 
older antidepressant initiators with high percentage of comorbidities at baseline, whereas 
fluoxetine was commonly used among young patients.     
 Keywords: Antidepressants; comorbidity; drug utilization study; Europe 
52 Introduction 
Antidepressants are among the most prescribed drugs in Europe.1 Besides depression as the 
major indication, antidepressants are also used for a wide range of other conditions such as panic 
disorders, generalized anxiety disorder, and neuropathic pain (Noordam et al., 2015). The most 
recent drug utilization studies conducted in Europe suggest an increase in the use of 
antidepressants over time, particularly for selective serotonin reuptake inhibitors (SSRIs), the 
most commonly prescribed type of antidepressant class (Abbing-Karahagopian et al., 2014; 
Bauer et al., 2008; Noordam et al., 2015; Poluzzi et al., 2013). 
In past decades, the number of antidepressants available on the market has increased markedly, 
resulting in a great variety of treatment options for prescribers. The choice of an antidepressant is 
influenced by several factors, including those specifically related to the drug profile (e.g. side 
effects, tolerability, and cost), physician characteristics (e.g. specialty, country of practice), 
reimbursement policies (Bauer et al., 2008), and patient characteristics, such as severity of 
depression and presence of comorbidities (Jobski et al., 2017b; Zimmerman et al., 2004).
With the exception of one German study restricted to adults older than 65 years (Jobski et al., 
2017b), no studies have analysed the use of antidepressants in adults from the general population 
in several European countries since 2012. Also, little information is available on the patterns of 
comorbidities among initiators of different antidepressant drugs. Therefore, we aimed to describe 
the cumulative incidence of initiators of 10 commonly prescribed antidepressants for the period 
1 CI = confidence interval; GePaRD = German Pharmacoepidemiological Research Database; IQR = interquartile range; NA = 
not applicable; NASSA = noradrenaline and specific serotonergic antidepressant; SIDIAP = Information System for the 
Research in Primary Care; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; TCA = tricyclic antidepressant.
62009-2014 in Denmark, Germany, Spain, and Sweden. We also aimed to compare the 
characteristics of initiators of each of the 10 study antidepressants in terms of their demographic 
characteristics, presence of comorbidities, health care resource use, and patterns of use. 
3 Methods
3.1 Study Setting
This drug utilization study was conducted using data collected during a postauthorisation safety 
study investigating the potential risk of acute hepatoxic reactions associated with the use of 
agomelatine and other antidepressants (Pladevall, 2018). Initiators of each study antidepressant 
were identified in four countries using five automated health data sources: the Danish National 
Health Registers (Denmark) (Pottegard et al., 2016; Schmidt et al., 2015), the German 
Pharmacoepidemiological Research Database (GePaRD) (Germany) (Jobski et al., 2017a; Jobski 
et al., 2017b; Pigeot and Ahrens, 2008), the EpiChron Cohort from Aragon Health Sciences 
Institute (Aragon, Spain) (Prados-Torres et al., 2018), the Information System for Research in 
Primary Care (SIDIAP) (Catalonia, Spain) (SIDIAP, 2014), and the Swedish National Registers 
(Sweden) (Ludvigsson et al., 2011; Wettermark et al., 2007). The main characteristics of each 
database are described in Supplementary Table 1. The study period in each data source started 
after the launch of agomelatine in each respective country (2009 or 2010) and ended on the last 
year for which data was available in each data source (2013 or 2014).
3.2 Study population
The study cohort included all adult initiators of any of the 10 relevant antidepressants in the 
study databases from 2009 to 2014 with at least 12 months of continuous enrolment in the data 
7source. The study cohort included all individuals aged 18 years or older at the date of the first-
recorded prescription fill for any of the study antidepressants during the study period(s) with no 
prescription fill for the same study antidepressant within the prior 12 months (initiators). One 
patient could contribute to several antidepressant groups if eligibility criteria were accomplished. 
For women, pregnancy at the start date of antidepressant use was an exclusion criterion.
3.3 Study antidepressants
The selected study antidepressants included five SSRIs (citalopram, escitalopram, fluoxetine, 
paroxetine, and sertraline), two serotonin-norepinephrine reuptake inhibitors (SNRIs) (duloxetine 
and venlafaxine), one tricyclic antidepressant (TCA) (amitriptyline), one noradrenaline and 
specific serotonergic antidepressants (NASSAs) (mirtazapine), and one melatonergic agonist and 
5-HT2C antagonist (agomelatine) (Supplementary Table 2). These antidepressants were selected 
in the agomelatine postauthorisation safety study to represent (1) the most commonly used 
antidepressants in the participating countries and (2) different classes of antidepressants. 
Agomelatine was selected for regulatory reasons as the main exposure of interest (Pladevall, 
2018). Specific details on the exposure definition are included in Supplementary Methods. 
Indication of use of study antidepressants for the study population was not available. 
3.4 Characterisation of initiators of study antidepressants
Initiators of the study antidepressants were characterised at the date of their first prescription 
according to age and sex. Comorbidity information at any time before cohort inclusion was 
ascertained through hospital discharge diagnoses and diagnoses reported in primary care, when 
available, in combination with information on the use of medications for specific diseases when 
8applicable (Pladevall, 2018). Information on hospitalisations during the 12 months prior to the 
current treatment episode was also collected as a measure of health care utilisation. 
Patterns of antidepressant use were also assessed. First, we measured the recent use of any 
antidepressant (N06A group) available on the market at the time of the study (0, 1, 2, or more) in 
the 12 months prior to the current treatment episode. Switching and multiple use were not 
differentiated but rather combined into a single variable. We also measured the duration of the 
first treatment episode of current use (in months). Finally, we measured whether the study 
antidepressants were prescribed alone or combined with other antidepressants by calculating the 
percentage of treatment episodes of current use with combined use of another antidepressant.
3.5 Statistical analyses
Data describing the study population and prescribing patterns of antidepressants are presented as 
means, standard deviations, frequencies, or percentages, as appropriate. The estimated 
cumulative incidence of antidepressant initiation at the end of the study period was calculated 
overall and for each antidepressant by dividing the total number of initiators and the number of 
initiators for each study antidepressant during the study period (2009 to 2013/2014) by the total 
reference adult population in each data source at the end of 2013 or 2014 (depending on the end 
of the study period). Stata (version 14) or SAS (version 9.4 or later) was used for the analyses by 
the different study research partners evaluating each of the individual data sources.
4 Results 
The study included a total of 4,833,774 initiators of antidepressants (Table 1). Sweden had the 
largest population with 1.8 million initiators of study antidepressants, followed by GePaRD 
9(Germany) with 1.7 million, Denmark with 0.8 million, and the Spanish populations (EpiChron 
[Aragon] and SIDIAP [Catalonia]) with less than 0.3 million each. 
4.1 Demographic characteristics of antidepressant initiators
Women comprised the majority of initiators for all antidepressants (Table 1). The study 
antidepressant with the highest proportion of women initiators was fluoxetine (>70% in four of 
five populations). In general, fluoxetine was prescribed to younger patients (median age range, 
38 years in Sweden to 50 years in Aragon [Spain]), and mirtazapine was consistently prescribed 
to older patients (median range, 54 years in Denmark to 67 years in Aragon [Spain]). Among 
SSRIs, citalopram was commonly prescribed among older patients (range, 51 years in Denmark 
to 63 years in Aragon [Spain]). 
4.2 Incidence of antidepressant initiation
The highest total cumulative incidence of antidepressant initiation for the 10 antidepressants (as 
per 1,000 population) during the period 2009 and 2013/2014 (depending on data source)  was 
found in Sweden with 234, followed by Denmark, 213; Aragon (Spain), 192; Catalonia (Spain), 
187; and Germany, 162 (Table 2). Overall, citalopram was the most prescribed study 
antidepressant, except in Aragon (Spain), with a cumulative incidence ranging from 10 per 1,000 
population in Aragon (Spain) to 65 per 1,000 population in Denmark. In Aragon (Spain), the 
most prescribed study antidepressant was escitalopram, with a cumulative incidence of 48 per 
1,000 population. For the other SSRIs, we observed higher rates for sertraline in Denmark and 
Sweden when compared with other populations. In contrast, rates for fluoxetine and paroxetine 
were higher in Aragon and Catalonia populations than in the other populations. The use of 
duloxetine and venlafaxine was similar in all populations, with a higher cumulative incidence for 
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venlafaxine when compared with that for duloxetine, except in Aragon (Spain). Except in 
Denmark where the cumulative incidence was lower (10 per 1,000 population), amitriptyline had 
a similar cumulative incidence in all populations (ranging from 21 to 29 per 1,000 population). 
The cumulative incidence for mirtazapine was the highest in Denmark, Germany (where it was 
the second most commonly used antidepressant), and Sweden (where it was the third). Finally, 
the use of agomelatine was low in all populations, with a cumulative incidence below 10 per 
1,000 population in all data sources.
4.3 Baseline comorbidities of antidepressant initiators
The most prevalent comorbidities at baseline (percentage and 95% confidence interval) in the 
study antidepressant initiators were hypertension, diabetes, hyperlipidaemia, and obesity (Table 
3). The highest prevalence of hypertension was found among initiators of mirtazapine in Aragon 
(55%) and Catalonia (38%) (Spain) and Sweden (48%) and among initiators of amitriptyline in 
in Denmark (38%). In Germany, the highest prevalence of hypertension was found equal among 
initiators of amitriptyline and mirtazapine (63%). A similar pattern, although with lower 
prevalence compared with hypertension, was observed for other comorbidities. Conversely, the 
percentage of patients with obesity at baseline was higher among fluoxetine initiators and lower 
for mirtazapine initiators. 
4.4 Hospitalisations in the 12 months prior to start date among 
antidepressant initiators
The number of hospitalisations among initiators of study antidepressants during the 12 months 
before the study start varied among populations, although a common pattern emerged. 
Mirtazapine initiators were more frequently hospitalised compared with initiators of the 
11
remaining study antidepressants in Aragon and Catalonia, Spain, and Sweden (percentages of at 
least one hospitalisation were 23%, 17%, and 33%, respectively). (Table 4). Although initiators 
of amitriptyline had the highest proportion of patients who had been hospitalised in the previous 
year in Denmark (37% of patients had at least 1 hospitalisation), the proportion of patients with 
recent hospitalisations was also high for initiators of mirtazapine (33% of patients with at least 1 
hospitalisation). Similarly, in Germany initiators of duloxetine and escitalopram (56% and 48% 
of patients with at least one hospitalisation, respectively) had the highest proportion of patients 
who had been hospitalised in the previous year, followed by initiators of mirtazapine (47% of 
patients with at least one hospitalisation).   
4.5 Patterns of antidepressant use among initiators
The recent use of any antidepressant during the 12 months prior to the current treatment episode 
is presented in Figure 1. In all populations, citalopram initiators were among the patients with the 
highest proportions of no antidepressant use in the 12 months prior to the current treatment 
episode. Amitriptyline had the highest proportion with no use in Aragon and Catalonia (Spain) 
and in Germany. Conversely, the two SNRIs (duloxetine and venlafaxine) and agomelatine were 
the antidepressants with the higher proportion of patients who used two or more antidepressants 
during the 12 months prior to the current treatment episode (Figure 1). Among the five 
populations, the overall proportion of initiators with no previous use of other study 
antidepressants in the 12 months prior to the current treatment episode was highest in Spain, 
Germany, and Denmark and lowest in Sweden. 
Patterns regarding duration of the first treatment episode of current use and percentage of all 
treatment episodes of current use with combined use of other antidepressants during the study 
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period are presented in Table 5. For all study antidepressants, the duration of the first treatment 
episode of current use was slightly longer in Catalonia (Spain) (range, 4 months for amitriptyline 
to 10 months for venlafaxine) and shorter in Germany (range, 2 months for amitriptyline to 4 
months for fluoxetine) than in the other populations. The median duration of the first index 
episode was longer for venlafaxine initiators and shorter for amitriptyline initiators in all 
populations except in Sweden. The highest percentage of patients in the five populations who 
were using combined antidepressants during their current treatment episode was found in 
initiators of agomelatine, followed by venlafaxine and duloxetine initiators (in Denmark, 
amitriptyline also had a high percentage of multiple use). 
5 Discussion 
In this study, we characterised more than 4.8 million initiators of ten antidepressants in Spain, 
Germany, Denmark, and Sweden. Overall, citalopram was the most prescribed study 
antidepressant, followed by mirtazapine. Agomelatine (one of the most recent study 
antidepressants available on the market) and paroxetine, were the least commonly prescribed 
antidepressants. Mirtazapine initiators were older compared to initiators of other antidepressants. 
Consequently, mirtazapine initiators had the highest percentage of comorbidities at baseline and 
also more hospitalisations in the 12 months prior to start date. Fluoxetine was the most common 
study antidepressant among younger and healthier initiators. Finally, citalopram and 
amitriptyline were the antidepressants with the lowest percentages of initiators who had used 
other antidepressant drugs in the 12 months prior to the current treatment episode, while 
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agomelatine and SNRIs (duloxetine and venlafaxine) initiators had the highest percentage of 
antidepressants use in the year prior to the current treatment episode. 
The results of the present study, which highlight citalopram as the most commonly prescribed 
among study antidepressant initiators in all populations but in Aragon (Spain), where 
escitalopram was the most often prescribed antidepressant, are in accordance with clinical 
guidelines to manage major depressive disorder in adults (Cipriani et al., 2018; National Institute 
for Health and Clinical Excellence, 2018b). The clinical guidelines for depression suggest using 
an SSRI (mostly citalopram, fluoxetine, and sertraline) as first-line treatment in adults (National 
Institute for Health and Clinical Excellence, 2018b). If clinical response is not adequate, the 
guidelines suggest a different SSRI agent or a newer generation antidepressant like mirtazapine, 
which was the second most prescribed antidepressant in Denmark, Germany, and Sweden. It was 
however unexpected that mirtazapine initiators in all populations but Sweden had a low 
percentage of prior use of other antidepressants in the 12 months prior to cohort inclusion, 
suggesting that mirtazapine may to some extent be used as a first-line agent in the studied 
populations. The faster onset of action and the more sedative effect of mirtazapine compared 
with SSRIs in the acute phase of depression might explain these results (Watanabe et al., 2011). 
Reimbursement policies vary by antidepressant in each of the participating countries, and this 
could potentially explain the observed variability in patterns of use of antidepressants. As an 
example, the study revealed differences in prescriptions in the two Spanish populations, with 
escitalopram being more frequently prescribed in Aragon, while citalopram was the number one 
option in Catalonia.
Overall, more than 50% of the antidepressant initiators receiving SSRIs (mostly citalopram and 
sertraline) had no prior use of other antidepressants, and a very low proportion of these patients 
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used two or more antidepressants in the 12 months prior to current treatment episode, except in 
Sweden. Also, most SSRI initiators in the five populations did not have combined use with other 
antidepressants during the current treatment episode. Both results suggest that, in general, 
citalopram and to a minor degree sertraline, escitalopram, paroxetine, and fluoxetine were mostly 
used as first-line treatment and used in monotherapy. On the other hand, the two SNRIs included 
in the study, duloxetine and venlafaxine, as well as agomelatine were seemingly mostly used as 
second-line treatment, in agreement with clinical guidelines for major depression (National 
Institute for Health and Clinical Excellence, 2018b). This interpretation is also supported by the 
high proportion of patients who used two or more antidepressants in the 12 months prior to start 
date as well as by the high percentage of patients who used other antidepressants concomitantly 
during the study period. However, of the antidepressants included in this study, duloxetine, 
venlafaxine, and agomelatine are the ones introduced in the European Union market more 
recently, which could explain these results. 
The main results discussed in the present study are focused on management of depression, but all 
the study antidepressants are also used in other conditions, which may explain some of the 
results observed in the present study. For example, our results suggest that the TCA 
amitriptyline, for which we found mostly was mainly used as monotherapy use, and a very low 
use of other antidepressants in the 12 months prior to the current treatment episode. Although 
this could suggest a was uncommon. Amitriptyline is recommended as first-line treatment use in 
depression, amitriptyline is known to be mostly used in other pathologies, includingthe 
management of neuropathic pain (Fornasari, 2017; National Institute for Health and Clinical 
Excellence, 2018a) and can also be used in the context of migraine, stress, and sleep disorders 
(Aarts et al., 2016; Moore et al., 2012, 2015), and fibromyalgia . For these indications, 
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amitriptyline can be used as monotherapy, which accords with the observations from Germany, 
Sweden, and Spain, or in combination with pregabalin/gabapentin, opioids, or SNRIs (Holbech 
et al., 2017)Similarly. Finally, the two SNRIs in the study, duloxetine and venlafaxine, as well as 
the SSRIs are approved treatments for anxiety disorders (Aarts et al., 2016).
The present study revealed that initiators of study antidepressants frequently had several 
comorbidities, hypertension being the most frequent. Mirtazapine was the most prescribed 
antidepressant among patients with a higher percentage of comorbidities at baseline, which is 
probably related to the fact that mirtazapine initiators were the oldest initiators in all populations 
(median age range, 54-67 years). The unique adverse event profile of mirtazapine including 
sedation and increase in appetite may justify its use in older patients compared with other 
antidepressants (Watanabe et al., 2011). It is important to note that mirtazapine and amitriptyline, 
particularly in the Nordic countries, were the most commonly prescribed antidepressants among 
patients presenting comorbidities such as hypertension, diabetes, or hyperlipidaemia, which does 
not reflect the clinical guidelines that recommend the use of citalopram or sertraline in these 
patient groups (National Institute for Health and Clinical Excellence, 2018b) which may be 
partly explained for the approved use in other conditions. Conversely, fluoxetine initiators were 
younger compared to mirtazapine initiators and had the lowest percentage of comorbidities at 
baseline among all study antidepressants. These results are likely associated with the high 
efficacy of fluoxetine in reducing depressive symptoms in children and adolescents (Cipriani et 
al., 2016). For obesity, the percentage was higher among fluoxetine initiators and lower among 
mirtazapine initiators, which is in accordance with previous evidence that relates mirtazapine to a 
greater risk of weight gain and fluoxetine with weight loss (Gafoor et al., 2018). Because we 
were not able to differentiate whether differences in prevalence of comorbidities between 
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countries reflected an actual variation or differences in the type of data available in each 
population, this could not be further interpreted. 
6 Limitations
The results of the present study should be interpreted in the context of its limitations. First, 
although the data sources provide detailed information on filled prescriptions, which can be 
considered complete, this information may not reflect actual use. However, information on 
dispensing more closely reflects actual use by the patients than information obtained by 
prescribing data (Pottegard et al., 2014). Second, the present study used a new-user design and 
then focused on initiators of each of the study antidepressants only. Therefore, prevalent users 
have not been evaluated. Third, the lack of information on the indication of medications in the 
present study hampered the possibility of studying the differences in the indications across the 
different study antidepressants and data sources. For this reason, discussion on the present study 
focuses on depression and not on other conditions that can be treated with the study 
antidepressants. Fourth, only a selected group of antidepressants have been included in the 
present study, based on the list of antidepressants included in the Agomelatine PASS (Pladevall, 
2018), and therefore the results of this study did not include all available antidepressants in the 
ATC N06A group. Finally, the heterogeneity of health care systems and of the type of data 
across data sources needs to be considered when evaluating comorbidities associated with the 
different antidepressants. Information recorded in SIDIAP (Catalonia, Spain) and EpiChron 
(Aragon, Spain) data sources is based on primary care and hospital discharge electronic medical 
records, information recorded in the GePaRD (Germany) data source is based on insurance 
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claims from ambulatory care visits and hospitalisations, and information in Denmark and 
Sweden registers is based on hospital diagnoses only. 
On the other hand, the present study has a number of strengths. The present study presented data 
from 2009 to 2014, the most recent period reported in the literature. In addition, it is one of the 
largest drug utilization studies on the use of antidepressants in Europe, including almost 5 
million initiators in Spain, Germany, Denmark, and Sweden covering a base population of more 
than 36 million people. Also, we have studied a number of important comorbidities at baseline. 
Finally, we have well-defined populations with prospectively collected data. 
7 Conclusions
Results of this study conducted in Denmark, Germany, Spain, and Sweden including 4.8 million 
initiators of study antidepressants suggest that citalopram and mirtazapine are the most 
commonly used antidepressants, followed by other SSRIs (sertraline, escitalopram, paroxetine, 
and fluoxetine). Mirtazapine was the second most used antidepressant in most of the populations. 
Agomelatine, which is commonly used as second-line treatment, and paroxetine were the least 
used antidepressants in the participating populations. Mirtazapine was the antidepressant most 
commonly prescribed among older study antidepressant initiators and was the one with the 
highest percentage of comorbidities in patients at baseline and with the highest number of 
hospitalisations. Fluoxetine was commonly prescribed among young patients with a low 
percentage of comorbidities at baseline.      
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Table 1. Number of study antidepressant initiators with age and sex distribution 
Denmark GePaRD, Germany
EpiChron, Aragon, 
Spain
SIDIAP, Catalonia, 
Spain Sweden
Study period
Number of study 
antidepressant initiators, 
n (%)
Citalopram 253,531 (30%) 463,794 (27%) 10,412 (5%) 53,076 (20%) 405,944 (22%)
Escitalopram 57,184 (7%) 77,765 (5%) 52,256 (25%) 29,429 (11%) 141,701 (8%)
Fluoxetine 18,448 (2%) 66,782 (4%) 17,045 (8%) 23,784 (9%) 77,044 (4%)
Paroxetine 18,968 (2%) 50,141 (3%) 26,213 (12%) 38,883 (15%) 34,666 (2%)
Sertraline 137,644 (16%) 88,200 (5%) 12,899 (6%) 28,101 (11%) 359,636 (20%)
Duloxetine 37,514 (4%) 79,456 (5%) 23,744 (11%) 13,509 (5%) 86,454 (5%)
Venlafaxine 87,390 (10%) 147,580 (9%) 11,951 (6%) 15,577 (6%) 130,716 (7%)
Amitriptyline 39,404 (5%) 309,377 (18%) 22,716 (11%) 33,870 (13%) 204,078 (11%)
Mirtazapine 167,020 (20%) 370,741 (22%) 23,971 (11%) 20,324 (8%) 347,596 (19%)
Agomelatine 21,941 (3%) 62,009 (4%) 10,077 (5%) 4,167 (2%) 19,046 (1%)
Total 839,044 1,715,845 211,284 260,720 1,806,881
Women (%)
Citalopram 61% 67% 69.2% 70.4% 65.3%
Escitalopram 61% 66.7% 69.1% 67.1% 64.9%
Fluoxetine 69.9% 72.2% 75.2% 75% 73.5%
Paroxetine 60.5% 65.7% 71.5% 70.3% 60.5%
Sertraline 62.4% 67% 67.2% 69.8% 63.6%
Duloxetine 65.1% 69.3% 73.7% 75.1% 65.6%
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Denmark GePaRD, Germany
EpiChron, Aragon, 
Spain
SIDIAP, Catalonia, 
Spain Sweden
Venlafaxine 61.1% 65.9% 69.5% 70.2% 60.6%
Amitriptyline 65.3% 71.8% 74.6% 75.7% 69%
Mirtazapine 57.5% 65.9% 65.5% 64.7% 58.5%
Agomelatine 65% 68.3% 69.7% 67.4% 62.1%
Age, median (IQR), years
Citalopram 51 (36-70) 54 (42-70) 63 (46-79) 55 (41-71) 56 (39-75)
Escitalopram 52 (37-69) 51 (39-63) 56 (42-73) 51 (38- 67) 44 (32-59)
Fluoxetine 41 (29-54) 47 (36-57) 50 (39-63) 47 (37-59) 38 (26-51)
Paroxetine 44 (34-59) 49 (37-60) 53 (40-68) 49 (37-63) 45 (32-58)
Sertraline 44 (31-59) 52 (41-65) 62 (44-78) 61 (44-76) 43 (30-60)
Duloxetine 48 (37-60) 57 (47-70) 59 (46-73) 56 (45-68) 48 (37-61)
Venlafaxine 45 (33-57) 51 (40-61) 55 (43-70) 53 (42-67) 44 (32-58)
Amitriptyline 51 (41-65) 58 (47-71) 53 (40-67) 52 (39-65) 55 (43-68)
Mirtazapine 54 (40-72) 58 (47-73) 67 (49-81) 60 (45-76) 58 (41-76)
Agomelatine 46 (36-57) 52 (42-61) 54 (42-67) 51 (41-62) 45 (33-56)
IQR = interquartile range.
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Table 2. Cumulative incidence of study antidepressant initiation at the end of study period (per 1,000 population): 
Denmarka GePaRD, Germanyb
EpiChron, Aragon, 
Spainb
SIDIAP, 
Catalonia, 
Spaina Swedena
Citalopram 64.5 43.7 9.5 38.0 52.5
Escitalopram 14.5 7.3 47.5 21.1 18.3
Fluoxetine 4.7 6.3 15.5 17.0 10.0
Paroxetine 4.8 4.7 23.8 27.8 4.5
Sertraline 35.0 8.3 11.7 20.1 46.5
Duloxetine 9.5 7.5 21.6 9.7 11.2
Venlafaxine 22.2 13.9 10.9 11.1 16.9
Amitriptyline 10.0 29.2 20.6 24.2 26.4
Mirtazapine 42.5 35.0 21.8 14.5 45.0
Agomelatine 5.6 5.9 9.2 3.0 2.5
Total 213.3 161.8 192.0 186.5 233.8
a Population reference: adult population in the data source at 01 January 2014.
b Population reference: average of the adult population average between the size of the source population at the start of the study period (2009) 
and the end of the study period (2013).
c Population reference: adult population in the data source at 01 January 2013.
Note: The estimated cumulative incidence of study antidepressant initiation at the end of the study period was calculated by dividing the total 
number of initiators during the study period (2009 to 2013/2014) of each antidepressant by the total reference adult population in each data source 
at the end of 2013 or 2014 (depending on the end of the study period).
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Table 3. Comorbid conditions among study antidepressant initiators 
SSRIs,
% (95% CI)
SNRIs,
% (95% CI)
TCA,
% (95% CI)
NASSA,
% (95% CI)
Other,
% (95% CI)
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Denmark (n = 839,044)
Hypertension 33.3 
(32.1-34.5)
32.8 
(31.6-34.0)
20 
(19.0-21.0)
25.1 
(24.0-26.2)
25.1
(24.0-26.2)
30.2 
(29.0-31.4)
24.5
 (23.4-25.6)
37.6
 (36.3-38.9)
36.6
(35.3-37.9)
27.0
 (25.9-28.1)
31.1
(29.9-32.3)
Diabetes 8.4
 (7.8-9.0)
7.9
 (7.3-8.5)
5.5
 (5.0-6.0)
6
 (5.5-6.5)
6.7
 (6.1-7.3)
8.6
 (8.0-9.2)
6.7
 (6.1-7.3)
10.7
 (10.0-11.4)
8.6
 (6.0-9.2)
7.2
 (6.6-7.8)
7.9
(7.3-8.5)
Hyperlipidaemia 22.3
 (21.3-23.3)
21.5
 (20.5-22.5)
13.4
 (12.6-14.2)
16.8
 (15.9-17.7)
17.1
(16.2-18.0)
20.9
 (19.9-21.9)
17
 (16.1-17.9)
25.7
 (24.6-26.8)
24.3
(23.2-25.4)
19.3
 (18.4-20.2)
20.9
(19.9-21.9)
Obesity 7.3
 (6.7-7.9)
6.7
 (6.1-7.3)
10.4
 (9.7-11.1)
7.6
 (7.0-8.2)
8.4 
(7.8-9.0)
11.4
 (10.7-12.1)
9.7
 (9.0-10.4)
11.4
 (10.7-12.1)
6.4
 (5.9-6.9)
11.7
 (11.0-12.4)
8.1
(7.5-8.7)
History of 
cerebral arterial 
disease
10.9
 (10.2-11.6)
10.9
 (10.2-11.6)
3.7
 (3.3-4.1)
5.0
 (4.5-5.5)
5.8
 (5.3-6.3)
6.3
 (5.8-6.8)
5.2
 (4.7-5.7)
9.3
 (8.6-10.0)
10.4
 (9.7-11.1)
5.0
 (4.5-5.5)
8.6
(8.0-9.3)
History of 
ischaemic heart 
disease
10.4
 (9.7-11.1)
10.6
 (9.9-11.3)
5.3
 (4.8-5.8)
7.0
 (6.4-7.6)
7.6
 (7.0-8.2)
8.5
 (7.9-9.1)
6.9
 (6.3-7.5)
11.5
 (10.8-12.2)
11.7
(11.0-12.4)
7.6
 (7.0-8.2)
9.6
(8.9-10.2)
Chronic 
pulmonary 
disease
9.5
 (8.8-10.2)
9.3
 (8.6-10.0)
8.2
 (7.6-8.8)
8.5
 (7.9-9.1)
8.6
 (8.0-9.2)
9.4
 (8.7-10.1)
8.5
 (7.9-9.1)
11.8
 (11.1-12.5)
10.8
(10.1-11.5)
9.0
 (8.4-9.6)
9.5
(8-9-10.2)
Dementia 2.6
 (2.3-2.9)
3.4
 (3.0-3.8)
0.6
 (0.4-0.8)
0.6
 (0.4-0.8)
1.5
 (1.2-1.8)
1.1
 (0.9-1.3)
0.8
 (0.6-1.0)
1.1
 (0.9-1.3)
3.4
 (3.0-3.8)
0.7
 (0.5-0.9)
2.2
(1.9-2.5)
GePaRD, Germany (n = 1,715,845)
Hypertension 57
 (55.9-58.1)
52.3
 (51.2-53.4)
45.2
 (44.2-46.2)
50.3
 (49.2-51.4)
55.0
(53.9-56.1)
66.8
 (65.6-68.0)
52.7
 (51.6-53.8)
63.0
 (61.8-64.2)
63.0
(61.8-64.2)
55.3
 (54.2-56.4)
58.4
(57.3-59.6)
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% (95% CI)
SNRIs,
% (95% CI)
TCA,
% (95% CI)
NASSA,
% (95% CI)
Other,
% (95% CI)
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Diabetes 18.8
 (18.2-19.4)
16.3
 (15.7-16.9)
13.3
 (12.8-13.8)
13.9
 (13.3-14.5)
17.9
(17.3-18.5)
26.7
 (25.9-27.5)
15.8 
(15.2-16.4)
20.6
 (19.9-21.3)
20.5
(19.8-21.2)
16.1
 (15.5-16.7)
19.0
(18.4-19.7)
Hyperlipidaemia 45.1
 (44.1-46.1)
41.4
 (40.4-42.4)
35.9
 (35.0-36.8)
39.2
 (38.3-40.1)
43.7
(42.7-44.7)
53.2
 (52.1-54.3)
41.7
 (40.7-42.7)
49.9
 (48.8-51.0)
50.0
(48.9-51.1)
43.7
 (42.7-44.7)
46.3
(45.3-47.3)
Obesity 24.9
 (24.2-25.6)
23.2
 (22.5-23.9)
28.3
 (27.5-29.1)
22.9
 (22.2-23.6)
26.0
(25.2-26.8)
34.1
 (33.2-35.0)
25.7
 (24.9-26.5)
27.9
 (27.1-28.7)
24.0
(23.3-24.7)
27.2
 (26.4-28.0)
25.9
(25.1-26.6)
History of 
cerebral arterial 
disease
9.7
 (9.2-10.2)
8.6
 (8.2-9.0)
4.3
 (4.0-4.6)
5.1
 (4.8-5.4)
8.3
 (7.9-8.7)
9.2
 (8.7-9.7)
6.5
 (6.1-6.9)
7.5
 (7.1-7.9)
10.1
 (9.6-10.6)
5.8
 (5.4-6.2)
8.5
(8.0-8.9)
History of 
ischaemic heart 
disease
22.7
 (22.0-23.4)
19.9
 (19.2-20.6)
14.0
 (13.4-14.6)
17.8
 (17.2-18.4)
21.4
(20.7-22.1)
28.0
 (27.2-28.8)
18.5
 (17.9-19.1)
25.2
 (24.4-26.0)
26.9
(26.1-27.7)
19.8
 (19.1-20.5)
23.2
(22.2-23.9)
Chronic 
pulmonary 
disease
49.8
 (48.7-50.9)
49.0
 (48.0-50.0)
51.7
 (50.6-52.8)
49.5
 (48.4-50.6)
50.6
(49.5-51.7)
53.5
 (52.4-54.6)
50.1
 (49.0-51.2)
52.3
 (51.2-53.4)
50.6
(49.5-51.7)
52.5
 (51.4-53.6)
50.8
(49.7-51.9)
Dementia 5.9
 (5.5-6.3)
4.4
 (4.1-4.7)
1.6
 (1.4-1.8)
2.3
 (2.1-2.5)
5.5
 (5.1-5.9)
3.9
 (3.6-4.2)
3.5
 (3.2-3.8)
2.5
 (2.3-2.7)
6.3
 (5.9-6.7)
2.6
 (2.4-2.8)
4.6
(4.3-4.9)
EpiChron, Aragon, Spain (n = 211,284)
Hypertension 51.2
 (48.2-54.2)
43.4
 (40.6-46.2)
37.7
 (35.1-40.3)
37.4
 (34.8-40.0)
51.3
(48.3-54.3)
48.6
 (45.6-51.6)
41.5
 (38.8-44.2)
39.1
 (36.4-41.8)
55.2
(52.0-58.4)
41.7
 (39.0-44.4)
44.3
(41.5-47.2)
Diabetes 15.2
 (13.5-16.9)
11.9
 (10.4-13.4)
11.3
 (9.9-12.7)
9.4
 (8.1-10.7)
14.4
(12.8-16.0)
14.3
 (12.7-15.9)
11.7
 (10.2-13.2)
9.3
 (8.0-10.6)
15.9
(14.2-17.6)
11.2
 (9.8-12.6)
12.2
(10.7-13.7)
Hyperlipidaemia 37.4 
(34.8-40.0)
34.3
 (31.8-36.8)
30.8
 (28.4-33.2)
31.1
 (28.7-33.5)
39.1
(36.4-41.8)
40.2
 (37.5-42.9)
34.8
 (32.3-37.3)
32.7
 (30.3-35.1)
39.8
(37.1-42.5)
36.9
 (34.3-39.5)
35.3
(32.8-37.9)
31
SSRIs,
% (95% CI)
SNRIs,
% (95% CI)
TCA,
% (95% CI)
NASSA,
% (95% CI)
Other,
% (95% CI)
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Obesity 21.2 
(19.2-23.2)
19.8
 (17.9-21.7)
32.1
 (29.7-34.5)
19.1
 (17.2-21.0)
21.8
(19.8-23.8)
25.3
 (23.2-27.4)
21.0
 (19.0-23.0)
21.0
 (19.0-23.0)
18.2
(16.4-20.0)
22.5
 (20.5-24.5)
21.6
(19.7-23.6)
History of 
cerebral arterial 
disease
5.4
 (4.4-6.4)
4.3
 (3.4-5.2)
2.3
 (1.7-2.9)
2.4
 (1.7-3.1)
5.2
 (4.2-6.2)
4.1
 (3.2-5.0)
3.0
 (2.3-3.7)
3.3
 (2.5-4.1)
5.3
 (4.3-6.3)
3.1
 (2.3-3.9)
3.9
(3.0-4.7)
History of 
ischaemic heart 
disease
4.6
 (3.7-5.5)
3.7
 (2.9-4.5)
2.3
 (1.7-2.9)
2.7
 (2.0-3.4)
5.2
 (4.2-6.2)
3.9
 (3.1-4.7)
2.7
 (2.0-3.4)
2.5
 (1.8-3.2)
5.5
 (4.5-6.5)
3.3
 (2.5-4.1)
3.6 
(2.8-4.4)
Chronic 
pulmonary 
disease
9.4
 (8.1-10.7)
8.6
 (7.4-9.8)
8.8
 (7.5-10.1)
7.8
 (6.6-9.0)
9.6
 (8.3-10.9)
9.8
 (8.5-11.1)
7.9
 (6.7-9.1)
8.3
 (7.1-9.5)
10.7
 (9.3-12.1)
9.2
 (7.9-10.5)
9.0
(7.7-10.2)
Dementia 2.8
 (2.1-3.5)
1.8
 (1.2-2.4)
0.8
 (0.4-1.2)
0.9
 (0.5-1.3)
2.6
 (1.9-3.3)
1.5
 (1.0-2.0)
1.8
 (1.2-2.4)
0.7
 (0.3-1.1)
4.0
 (3.1-4.9)
1.3
 (0.8-1.8)
1.8
(1.2-2.3)
SIDIAP, Catalonia, Spain (n = 260,720)
Hypertension 33.9
 (31.7-36.1)
27.9
 (25.9-29.9)
23.4
 (21.5-25.3)
25.5
 (23.6-27.4)
40.7
(38.3-43.1)
33.3
 (31.1-35.5)
30.1
 (28.0-32.2)
27.9
 (25.9-29.9)
38.0
(35.6-40.4)
25.8
 (23.9-27.7)
30.9
(28.8-33.0)
Diabetes 12.5
 (11.1-13.9)
10.2
 (9.0-11.4)
9.6
 (8.4-10.8)
8.6
 (7.5-9.7)
15.2
(13.7-16.7)
13.1
 (11.7-14.5)
11.2
 (9.9-12.5)
10.2
 (9.0-11.4)
15.2
(13.7-16.7)
9.3
 (8.1-10.5)
11.5
(10.2-12.8)
Hyperlipidaemia 31.3
 (29.2-33.4)
26.2
 (24.2-28.2)
25.6
 (23.7-27.5)
26.3
 (24.3-28.3)
35.5
(33.2-37.8)
34.2
 (32.0-36.4)
31.7
 (29.5-33.9)
29.5
 (27.4-31.6)
34.7
(32.4-37.0)
29.1
 (27.0-31.2)
30.1
(28.0-32.2)
Obesity 18.6
 (16.9-20.3)
14.8
 (13.3-16.3)
24.2
 (22.3-26.1)
15.7
 (14.2-17.2)
20.2
(18.5-21.9)
20.6
 (18.9-22.3)
19.5
 (17.8-21.2)
18.7
 (17.0-20.4)
16.0
(14.5-17.5)
18.0
 (16.4-19.6)
18.4
(16.7-20.0)
History of 
cerebral arterial 
disease
5.0
 (4.1-5.9)
4.1
 (3.3-4.9)
2.2
 (1.6-2.8)
2.7
 (2.1-3.3)
5.8
 (4.9-6.7)
4.1
 (3.3-4.9)
3.9
 (3.1-4.7)
3.5
 (2.8-4.2)
6.4
 (5.4-7.4)
3.0
 (2.3-3.7)
4.1
(3.4-4.9)
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SSRIs,
% (95% CI)
SNRIs,
% (95% CI)
TCA,
% (95% CI)
NASSA,
% (95% CI)
Other,
% (95% CI)
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Chronic 
pulmonary 
disease
13.0
 (11.6-14.4)
11.5
 (10.2-12.8)
11.4
 (10.1-12.7)
11.5
 (10.2-12.8)
14.1
(12.7-15.5)
12.7
 (11.3-14.1)
12.3
 (11.0-13.6)
12.3
 (11.0-13.6)
15.4
(13.9-16.9)
11.6
 (10.3-12.9)
12.6
(11.2-14.0)
Dementia 2.6
 (2.0-3.2)
2.5
 (1.9-3.1)
0.6
 (0.3-0.9)
1.3
 (0.9-1.7)
2.7
 (2.1-3.3)
1.1
 (0.7-1.5)
2.0
 (1.5-2.5)
0.6
 (0.3-0.9)
5.2
 (4.3-6.1)
0.9
 (0.5-1.3)
2.0
(1.5-2.6)
Sweden (n = 1,806,881)
Hypertension 45.5
 (44.5-46.5)
33.1
 (32.3-33.9)
25.9
 (25.2-26.6)
32.1
 (31.3-32.9)
31.6
(30.8-32.4)
40.7
 (39.8-41.6)
31.8
 (31.0-32.6)
46.8
 (45.8-47.8)
48.0
(47.0-49.0)
36.6
 (35.7-37.5)
40.0
(39.1-40.9)
Diabetes 9.5
 (9.1-9.9)
6.2
 (5.8-6.6)
5.0
 (4.7-5.3)
5.4
 (5.1-5.7)
6.2
 (5.8-6.6)
9.9
 (9.4-10.4)
6.2
 (5.8-6.6)
10.2
 (9.7-10.7)
9.8
 (9.3-10.3)
6.4
 (6.0-6.8)
8.2
(7.8-8.6)
Hyperlipidaemia 22.2
 (21.5-22.9)
14.6
 (14.0-15.2)
9.8
 (9.3-10.3)
13.5
 (13.0-14.0)
14.5
(13.9-15.1)
19.9
 (18.4-19.6)
14.1
 (13.6-14.6)
23.4
 (22.7-24.1)
23.3
(22.6-24.0)
14.2
 (13.7-14.7)
18.9
(18.3-19.5)
Obesity 2.9
 (2.7-3.1)
3.5
 (3.2-3.8)
5.7
 (5.4-6.0)
3.2
 (2.9-3.5)
3.4
 (3.1-3.7)
5.9
 (5.5-6.3)
4.4
 (4.1-4.7)
4.7
 (4.4-5.0)
3.0
 (2.7-3.3)
5.5
 (5.2-5.8)
3.7
(3.4-4.0)
History of 
cerebral arterial 
disease
8.6
 (8.2-9.0)
3.8
 (3.5-4.1)
1.7
 (1.5-1.9)
2.4
 (2.2-2.6)
3.8
 (3.5-4.1)
3.5
 (3.2-3.8)
2.9
 (2.7-3.1)
5.1
 (4.8-5.4)
8.5
 (8.1-8.9)
2.1
 (1.9-2.3)
5.7
(5.3-6.0)
History of 
ischaemic heart 
disease
10.1
 (9.6-10.6)
4.9
 (4.6-5.2)
2.3
 (2.1-2.5)
4.2
 (3.9-4.5)
5.1
 (4.8-5.4)
5.7
 (5.4-6.0)
4.0
 (3.7-4.3)
8.2
 (7.8-8.6)
10.8
(10.3-11.3)
3.4
 (3.1-3.7)
7.5
(7.1-7.9)
Chronic 
pulmonary 
disease
8.3
 (7.9-8.7)
7.4
 (7.0-7.8)
7.6
 (7.2-8.0)
6.9
 (6.5-7.3)
7.3
 (6.9-7.7)
9.0
 (8.6-9.4)
7.4
 (7.0-7.8)
9.3
 (8.9-9.7)
9.6
 (9.1-10.1)
8.1
 (7.7-8.5)
8.3
(7.9-8.7)
Dementia 4.2
 (3.9-4.5)
1.7
 (1.5-1.9)
0.3
 (0.2-0.4)
0.6
 (0.5-0.7)
1.4
 (1.2-1.6)
0.9
 (0.8-1.0)
1.0
 (0.9-1.1)
0.7
 (0.6-0.8)
5.2
 (4.9-5.5)
0.4
 (0.3-0.5)
2.6
(2.3-2.8)
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CI = confidence interval, NASSA = noradrenaline and specific serotonergic antidepressant, SNRI = serotonin-norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake 
inhibitor, TCA = tricyclic antidepressant. 
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Table 4. Number of hospitalisations among study antidepressant initiators of each of the study antidepressants 
during the 12 months before the cohort inclusion date, by data source
SSRIs SNRIs TCA NASSA Other
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Denmark
 0 70.2% 68.4% 78.6% 76.9% 76.2% 73.6% 76.5% 62.9% 67.2% 77.8%
 1 17.6% 17.7% 14.3% 14.4% 15.2% 15.9% 14.8% 20.3% 18.0% 14.2%
2+ 12.1% 13.8% 7.1% 8.7% 8.6% 10.5% 8.7% 16.8% 14.8% 8.0%
GePaRD
 0 60.4% 52.0% 68.1% 65.2% 56.9% 44.1% 55.3% 56.7% 52.9% 53.9%
 1+ 39.6% 48.0% 31.9% 34.8% 43.1% 55.9% 44.7% 43.3% 47.1% 46.1%
EpiChron, 
Aragon, Spain
 0 84.2% 85.7% 89.5% 88.9% 82.7% 84.9% 86.1% 89.8% 76.7% 86.5%
 1 10.8% 10.1% 7.7% 8.3% 11.5% 10.6% 10.1% 7.9% 15.0% 9.8%
2+ 5.0% 4.2% 2.8% 2.9% 5.8% 4.5% 3.9% 2.4% 8.3% 3.7%
SIDIAP, Catalonia, 
Spain
 0 88.4% 88.8% 90.9% 91.4% 87.3% 88.7% 88.7% 90.1% 83.1% 91.4%
 1 8.7% 8.2% 7.3% 6.8% 9.4% 8.7% 8.8% 7.8% 11.7% 6.5%
2+ 3.0% 3.0% 1.9% 1.8% 3.3% 2.7% 2.5% 2.1% 5.2% 2.1%
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SSRIs SNRIs TCA NASSA Other
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Sweden
 0 73.8% 75.9% 80.2% 80.0% 79.3% 71.8% 76.7% 75.2% 66.8% 73.3%
 1 13.8% 12.8% 11.8% 11.6% 12.2% 14.8% 13% 13.4% 15.8% 13.6%
2+ 12.4% 11.2% 8.0% 8.4% 8.5% 13.4% 10.3% 11.4% 17.5% 13.1%
NA = not applicable, NASSA = noradrenaline and specific serotonergic antidepressant, SNRI = serotonin-norepinephrine reuptake inhibitor, SSRI 
= selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant. 
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Table 5. Duration of treatment and multiple use of study antidepressants, by study population 
SSRIs SNRIs TCA NASSA Others
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Denmark
Duration (months) 
of first treatment 
episode in current 
use, median 
(IQR)
7.0 
(4.6-15.4)
5.6
 (2.5-12.9)
6.5 
(5.1-13.5)
5.8
 (3.9-13.0)
6.7 
(5.4-13.9)
6.5
 (2.5-16.3)
8.2
 (5.2-18.7)
3.5
 (3.5-5.9)
4.8
 (2.6-9.4)
5.6
 (2.5-13.1)
Percentage of all 
treatment 
episodes (current 
use) with 
combined use of 
other 
antidepressant, 
median (IQR)
0
 (0-30.0)
9.5
 (0-62.6)
9.2 
(0-60.7)
0
 (0-46.7)
0
 (0-42.5)
34.8
 (1.2-99.4)
22.0
 (0-77.6)
40.8
 (0-100.0)
16.3
 (0-100.0)
69.2
 (7.7-100.0)
GePaRD
Duration (months) 
of first treatment 
episode in current 
use, median 
(IQR)
3.0
 (2.0-6.1)
3.0
 (2.0-7.1)
3.9 
(2.1-7.2)
3.0
 (2.0-6.2)
3.5
 (2.0-7.9)
2.3
 (1.8-5.0)
3.2
 (1.9-7.4)
1.8
 (1.5-2.4)
2.1
 (1.6-3.1)
2.7
 (2.2-5.6)
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SSRIs SNRIs TCA NASSA Others
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Percentage of all 
treatment 
episodes (current 
use) with 
combined use of 
other 
antidepressant, 
median (IQR)
0.0 
(0.0-51.0)
18.6
 (0.0-81.9)
1.7
 (0.0-
62.8)
2.8
 (0.0-70.5)
11.0
 (0.0-
78.2)
9.3
 (0.0-86.7)
26.4
 (0.0-94.5)
0.0
 (0.0-0.0)
0.0
 (0.0-82.0)
44.0
 (0.0-100.0)
EpiChron, 
Aragon, Spain
Duration (Months) 
of first treatment 
episode in current 
use, median 
(IQR)
3.3 
(2.2-7.9)
3.4
 (2.2-7.9)
3.5
 (2.2-7.7)
3.2
 (2.2-7.3)
3.5
 (2.3-8.3)
3.6
 (2.2-9.8)
4.0
 (2.3-10.3)
3.3
 (2.1-5.1)
3.3
 (2.3-7.3)
3.3
 (2.2-7.7)
Percentage of all 
treatment 
episodes (current 
use) with 
combined use of 
other 
antidepressant, 
median (IQR)
0 
(0-14.2)
0
 (0-6.9)
0
 (0-10.7)
0
 (0-10.7)
0
 (0-22.5)
0
 (0-33.5)
5.1
 (0-50.8)
0
 (0-1.4)
5.3
 (0-67.8)
25.0
 (0-74.5)
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SSRIs SNRIs TCA NASSA Others
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SIDIAP, 
Catalonia, Spain
Duration (months) 
of first treatment 
episode in current 
use, median 
(IQR)
7.6
 (3.2-17.5)
8.4
 (3.2-19.6)
7.3
 (3.3-16.9)
7.3
 (3.0-15.9)
7.3
 (3.0-16.3)
8.2
 (3.2-19.8)
9.7
 (3.5-22.2)
3.7
 (2.1-9.5)
6.3
 (2.4-15.0)
8.0
 (3.3-18.8)
Percentage of all 
treatment 
episodes (current 
use) with 
combined use of 
other 
antidepressant, 
median (IQR)
0.0
 (0.0-10.0)
0.0
 (0.0-19.9)
0.0
 (0.0-15.6)
0.0
 (0.0-10.6)
0.0
 (0.0-19.4)
3.9
 (0.0-49.3)
9.3
 (0.0-63.1)
0.0
 (0.0-0.0)
8.3
(0.0-100.0)
18.8
 (0.0-100.0)
Sweden
Duration (months) 
of first treatment 
episode in current 
use, median 
(IQR)
4.6
 (2.6-10.3)
3.3
 (2.1-7.2)
4.5
 (2.3-7.7)
4.6
 (2.1-7.9)
4.6
 (2.3-8.8)
2.2
 (1.7-4.5)
2.8
 (1.6-4.7)
4.6
 (2.6-5.9)
3.2
 (2.1-5.7)
2.2
 (1.4-4.1)
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SSRIs SNRIs TCA NASSA Others
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Percentage of all 
treatment 
episodes (current 
use) with 
combined use of 
other 
antidepressant, 
median (IQR)
0
 (0-14.5)
0
 (0-50.2)
0
 (0-42.6)
0
 (0-39.1)
0
 (0-25.0)
17.4
 (0-77.2)
19.2
 (0-72.9)
0
 (0-14.8)
15
 (0-95.9)
69.2
 (0-100.0)
CI = confidence interval, IQR = interquartile range, NA = not applicable, NASSA = noradrenaline and specific serotonergic antidepressant, SNRI = 
serotonin-norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant.
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Supplementary Material 
Supplementary Table 1. Characteristics of the Databases
ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th Revision; 
ICD-10-CM = International Statistical Classification of Diseases and Related Health Problems, 10th 
Revision, Clinical Modification; ICD-10-GM = International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision, German Modification; ICD-9-CM = International Classification of 
Diseases, Ninth Revision, Clinical Modification; ICPC = International Classification of Primary Care; OPS 
= Operationen- und Prozedurenschlüssel.
Note: The term “filled prescriptions” is equivalent to dispensed medications.
Supplementary Table 2. List of study antidepressants
ATC = Anatomical Therapeutic Chemical (classification system).
Supplementary Methods 
Figure 1. Proportion of study antidepressants initiators by antidepressant 
treatment in the 12 months before drug initiation (no previous treatment, one 
antidepressant, two or more antidepressants)  
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NASSA = noradrenaline and specific serotonergic antidepressant, SNRI = serotonin-norepinephrine 
reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant. 
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Supplementary Table 1. Characteristics of the Databases
Database feature
Danish National 
Health Registers
GePaRD (German 
Pharmacoepidemiol
ogical Research 
Database)
EpiChron, Aragon, 
Spain
SIDIAP, Catalonia, 
Spain (Information 
System for Research 
in Primary Care)
Swedish National 
Prescription and 
Inpatient Databases
Population of 
country
Denmark: 5,627,235 Germany: 
80,767,463
Spain: 46,512,199 Spain: 46,512,199 Sweden: 9,644,864 
Database 
population (Million)
5.6 23.9 1.3 2.0 9.6
Database type National health record 
databases, link to 
other national 
databases through 
the unique Civil 
Personal Registration 
Number
Claims database, four 
statutory health 
insurance providers
Primary health care 
electronic medical 
record database; link 
to hospital discharge 
data and pharmacy 
data 
Primary health care 
electronic medical 
record database, link 
to hospital discharge 
data, pharmacy data, 
and mortality data
National health record 
databases, link to 
other national 
databases through 
the unique Civil 
Personal Registration 
Number
Data on 
medications and 
type of 
prescriptions
All (reimbursed and 
non-reimbursed) 
pharmacy-filled 
prescriptions; in one 
database, only 
reimbursed 
prescriptions
Reimbursed, 
pharmacy-filled 
prescriptions
Reimbursed, 
pharmacy-filled 
prescriptions
Reimbursed, 
pharmacy-filled 
prescriptions and 
electronically 
prescribed drugs
All (reimbursed and 
non-reimbursed) 
pharmacy-filled 
prescriptions
Database feature
Danish National 
Health Registers
GePaRD (German 
Pharmacoepidemiol
ogical Research 
Database)
EpiChron, Aragon, 
Spain
SIDIAP, Catalonia, 
Spain (Information 
System for Research 
in Primary Care)
Swedish National 
Prescription and 
Inpatient Databases
Drug dictionary 
codes/ therapeutic 
classification
ATC ATC ATC ATC ATC
Disease and 
procedure coding 
system(s)
ICD-10 ICD-10-GM for 
diagnoses; OPS for 
surgical and 
diagnostic 
procedures; EBM for 
types of treatments 
and diagnostic 
procedures
Primary health care, 
ICPC; hospital, 
ICD-9-CM 
ICD-10-CM for 
primary care 
diagnoses; 
ICD-9-CM for hospital 
diagnoses
ICD-10
Primary care data 
available
No Yes Yes Yes No
Specialist 
outpatient visits 
available
Only hospital clinic 
visits
Yes Yes Only referrals from 
primary care 
physician to hospital 
specialist; only the 
date of the first visit is 
recorded
Yes
Hospital discharge 
data available
Yes Yes Yes Yes Yes
Database feature
Danish National 
Health Registers
GePaRD (German 
Pharmacoepidemiol
ogical Research 
Database)
EpiChron, Aragon, 
Spain
SIDIAP, Catalonia, 
Spain (Information 
System for Research 
in Primary Care)
Swedish National 
Prescription and 
Inpatient Databases
Laboratory 
(requests, results)
No (results available 
only via abstraction of 
medical records)
Requests are 
available, but not 
results
Yes (only primary 
care results, hospital 
results available via 
abstraction of medical 
records)
Yes (only primary 
care results)
No
Data availability Patient register, since 
1977; prescription 
registers, since 1995;
last year included in 
this report, 2014
Since 2004 Partial since 2005; 
complete 2010 
through 2014
2006 through Dec 
2014
Since July 2005 
(patient register data 
available since 1987)
 Last year included in 
this report, 2014
Approximate time 
lag (updates per 
year) 
1 year (1 per year) 1.5-1.8 year (at least 
1 per year)
1 year (1 per year) 1 year (1 per year) 12 months (monthly 
updates for the 
prescribed drugs 
register)
Access to hospital 
medical records
Yes No Yes No No
ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10th Revision; ICD-10-CM = International Statistical 
Classification of Diseases and Related Health Problems, 10th Revision, Clinical Modification; ICD-10-GM = International Statistical Classification 
of Diseases and Related Health Problems, 10th Revision, German Modification; ICD-9-CM = International Classification of Diseases, Ninth 
Revision, Clinical Modification; ICPC = International Classification of Primary Care; OPS = Operationen- und Prozedurenschlüssel.
Note: The term “filled prescriptions” is equivalent to dispensed medications.
Supplementary Table 2. List of study antidepressants
Antidepressant Class ATC code
Citalopram Selective serotonin reuptake inhibitor N06AB04
Escitalopram Selective serotonin reuptake inhibitor N06AB10
Fluoxetine Selective serotonin reuptake inhibitor N06AB03
Paroxetine Selective serotonin reuptake inhibitor N06AB05
Sertraline Selective serotonin reuptake inhibitor N06AB06
Venlafaxine Serotonin-noradrenaline reuptake inhibitor (SNRIs) N06AX16
Duloxetine selective serotonin and norepinephrine reuptake 
inhibitor (SNRI)
N06AX21
Amitriptyline Tricyclic antidepressant (TCA) N06AA09
Mirtazapine Noradrenaline and specific serotonergic 
antidepressant (NASSAs)
N06AX11
Agomelatine Melatonergic agonist and 5-HT2C antagonist N06AX22
ATC = Anatomical Therapeutic Chemical (classification system).
SUPPLEMENTARY METHODS 
We defined exposure to study antidepressants as the number of days of supply of each 
prescription fill plus a period of 40 days. Days of supply were the assumed number of days of 
treatment associated with each prescription fill. The period of 40 days was added to account for 
stockpiling and less than perfect adherence (Sikka et al., 2005). Since the exact start date of 
medication use could not be ascertained from the data, it was assumed that treatment started on 
the day of the first prescription fill. For each person, exposure to each individual study 
antidepressant was ascertained using the estimated days of supply of each prescription fill. Days 
supplied information was available in the prescriptions in SIDIAP and in the Swedish registries. 
In the rest of databases, days of supply were estimated as follows: 
- In Denmark, days supplied were derived from assumed regimen (e.g., 1 pill per day) and 
number of tablets within the number of packages dispensed.
- In GePaRD (Germany), days supplied were derived from defined daily dose (DDD). 
- In EpiChron (Spain), DDDs were used to calculate days supplied. DDDs were derived 
from the number of boxes (and pills inside boxes) in each prescription. For all 
antidepressants, it was assumed that the dose was one pill a day.
